An interventional study of RefluxStop™ implantation and Nissen fundoplication in GERD (Gastroesophageal Reflux Disease), sponsored by Implantica CE Reflux Ltd.. Not yet recruiting at 4 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-04.
Sponsored by Implantica CE Reflux Ltd. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 70 studies in Gastroesophageal Reflux with a site in Germany — 7 open to participants now, 8 under way, none of them phase 3. Gastroesophageal Reflux · Germany.
Among the 70 studies in Gastroesophageal Reflux with a site in Germany, this one is the 27th largest by planned enrollment of the 54 interventional ones that give a count, is one of 4 that started in 2025, is one of 14 with no phase, and was the 66th registered.
1,216 studies on the registry are indexed under Gastroesophageal Reflux; 204 are open to participants now.
Browse Gastroesophageal Reflux studies →7 of the 70 studies in Gastroesophageal Reflux with a site in Germany are open now. Recruiting first, the newest first:
Bayer · Sites in Germany
Ages 18+
Universitair Ziekenhuis Brussel · Sites in Germany, Belgium
Ages 18–80
Implantica CE Reflux Ltd. · Sites in Germany, Italy, Norway and 1 more country
Ages 18+
Medtronic Cardiovascular · Sites in Germany, Denmark, France and 5 more countries
Ages 18+
Atrial Fibrillation Network · Sites in Germany
Ages 18+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 134 Gastroesophageal Reflux studies recruiting now, 58 (43%) set no upper age limit and 53 (40%) stop at 75 or younger; 22 take children under 18; 20 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
70 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 10 · Phase 3 21 · Phase 4 6
First in 2000; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is above the median of 68 across 800 interventional studies indexed under Gastroesophageal Reflux.
Median enrollment 180 across the 54 interventional studies, 404 across the 16 observational. Of the 55 that completed or were terminated, 20 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
58 of 70 have an industry lead sponsor. The 10 most frequent:
Implantica CE Reflux Ltd. is the lead sponsor of 4 studies on the registry; 3 are open to participants now.
Implantica CE Reflux Ltd. has 4 studies filed under Gastroesophageal Reflux — fewer than ten, so there is no comparison to draw.
2 of the studies in Gastroesophageal Reflux with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07004400Implantica CE Reflux Ltd.A Blinded Randomized Clinical Study of RefluxStop™ Compared With Nissen Fundoplication in the Treatment of GERD | 2026-12-01 |
| NCT07291700BayerStudy on Hydrotalcite for Relief of Acid Symptoms Due to Acid Rebound After Stopping Long-Term PPI Therapy | 2027-10-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 70 studies in Gastroesophageal Reflux with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will evaluate if the RefluxStop™ device will treat your acid reflux and improve your symptoms and how it compares to the standard surgical treatment for GERD, the Nissen fundoplication.
This study is a post-market prospective, blinded, randomized, multicenter, multi-arm clinical investigation using standard clinical procedures to record data to evaluate the safety and performance of RefluxStop™ compared with standard Nissen fundoplication for the treatment of subjects suffering from GERD.
A randomization will be performed where the Subjects will be blinded as to assigned randomization group.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Standard surgical technique for implantation RefluxStop™, as described in the Instructions for Use
Device: RefluxStop™ implantation
Standard surgical technique of Nissen fundoplication
Procedure: Nissen fundoplication
Standard surgical technique for implantation RefluxStop™, as described in the Instructions for Use
Standard surgical technique for Nissen fundoplication
Patient Reported Outcomes - Side effects (PROS) evaluation
Patient Reported Outcomes - Side effects (PROS) evaluation at 6 months, combining the well-established side effects of traditional surgical treatment methods: * Dysphagia - swallowing difficulties; * Odynophagia - pain at swallowing; * Inability to belch and inability to vomit; and * Worsening of gas bloating compared to baseline;
Time frame: 6 months
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Aug 2025; primary completion for Dec 2026, 16 months later.
Of 34 industry-sponsored interventional studies with no phase under Gastroesophageal Reflux, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 16 months is below that.
Counting every sponsor, half of 228 studies reached it within 32 months; a quarter within 12 and three quarters within 68.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Implantica CE Reflux Ltd.